Literature DB >> 9247610

Pharmacokinetic study of carboplatin given on a 5-day intravenous schedule.

Y Ando1, H Minami, H Saka, M Ando, S Sugiura, S Sakai, K Shimokata.   

Abstract

We investigated whether carboplatin pharmacokinetics is altered when the drug is delivered daily over 5 days, compared to a single-day infusion. Carboplatin was infused in 11 patients with lung cancer, who were randomly assigned to 2 groups. In the first group, the agent was administered on a conventional single-day schedule in the first course and then on a 5-day schedule in the second course. In the second group, the order was reversed (crossover design). The dose was calculated using Calvert's formula with 24 h creatinine clearance (Ccr, ml/min) as a substitute for glomerular filtration rate (GFR): carboplatin (mg) = AUCx(Ccr+25), where AUC denotes the area under the concentration versus time curve (mg ml-1 min). No difference of carboplatin clearance between the single-day and 5-day schedule was observed (94.8 +/- 19.9 versus 96.1 +/- 29.9 ml/min, P = 0.818, paired t test). The formula systematically overestimated the carboplatin clearance: the ratio of estimated clearance/ observed clearance ranged from 1.01 to 1.58 (median 1.28; 95% confidence interval, 1.18 to 1.39). We concluded that the individual dosing strategy based on renal function can be applied with a 5-day schedule as well as a single-day schedule. Carboplatin is overdosed when Ccr is substituted for GFR in Calvert's formula.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247610      PMCID: PMC5921454          DOI: 10.1111/j.1349-7006.1997.tb00412.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  17 in total

1.  Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination.

Authors:  L J van Warmerdam; S Rodenhuis; O van Tellingen; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  The two-period cross-over clinical trial.

Authors:  M Hills; P Armitage
Journal:  Br J Clin Pharmacol       Date:  1979-07       Impact factor: 4.335

3.  A limited sampling method for estimation of the carboplatin area under the curve.

Authors:  B T Sørensen; A Strömgren; P Jakobsen; A Jakobsen
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Phase I clinical and pharmacologic trial of carboplatin daily for 5 days.

Authors:  D A Van Echo; M J Egorin; M Y Whitacre; E A Olman; J Aisner
Journal:  Cancer Treat Rep       Date:  1984-09

5.  Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.

Authors:  L J van Warmerdam; S Rodenhuis; W W ten Bokkel Huinink; R A Maes; J H Beijnen
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

6.  Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Authors:  S J Harland; D R Newell; Z H Siddik; R Chadwick; A H Calvert; K R Harrap
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

7.  Phase I study of carboplatin given on a five-day intravenous schedule.

Authors:  M Rozencweig; C Nicaise; M Beer; N Crespeigne; M Van Rijmenant; L Lenaz; Y Kenis
Journal:  J Clin Oncol       Date:  1983-10       Impact factor: 44.544

8.  Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose.

Authors:  G Daugaard; N Rossing; M Rørth
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Response of nude mouse-grown human urothelial cancer to cis-diamminedichloroplatinum(II), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and mitoguazone dihydrochloride.

Authors:  A P Kyriazis; A Yagoda; A A Kyriazis; J Fogh
Journal:  Cancer Res       Date:  1985-05       Impact factor: 12.701

10.  Pharmacokinetics of carboplatin at a dose of 750 mg m-2 divided over three consecutive days.

Authors:  P O Mulder; E G de Vries; D R Uges; A H Scaf; D T Sleijfer; N H Mulder
Journal:  Br J Cancer       Date:  1990-03       Impact factor: 7.640

View more
  2 in total

1.  Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.

Authors:  Y Ando; H Minami; H Saka; M Ando; S Sakai; K Shimokata
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 2.  Carboplatin dosing for adult Japanese patients.

Authors:  Yuichi Ando; Tomoya Shimokata; Yoshinari Yasuda; Yoshinori Hasegawa
Journal:  Nagoya J Med Sci       Date:  2014-02       Impact factor: 1.131

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.